123 related articles for article (PubMed ID: 3881949)
1. Aztreonam in the treatment of serious orthopedic infections.
Pribyl C; Salzer R; Beskin J; Haddad RJ; Pollock B; Beville R; Holmes B; Mogabgab WJ
Am J Med; 1985 Feb; 78(2A):51-6. PubMed ID: 3881949
[TBL] [Abstract][Full Text] [Related]
2. Treatment of gram-negative infections with aztreonam.
Simons WJ; Lee TJ
Am J Med; 1985 Feb; 78(2A):27-30. PubMed ID: 4038577
[TBL] [Abstract][Full Text] [Related]
3. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli.
Simons WJ; Lee TJ
Rev Infect Dis; 1985; 7 Suppl 4():S783-8. PubMed ID: 2934786
[TBL] [Abstract][Full Text] [Related]
4. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
Scully BE; Neu HC
Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
[TBL] [Abstract][Full Text] [Related]
5. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
Henry SA; Bendush CB
Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
[TBL] [Abstract][Full Text] [Related]
6. Current state of infectious diseases--potential areas of directed therapy with aztreonam.
Neu HC
Am J Med; 1985 Feb; 78(2A):77-80. PubMed ID: 4038580
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of aztreonam against gram negative bacteria from clinical specimens and its comparison with other commonly used antibiotics.
Qadri SM; Belobraydic KA
Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):223-6. PubMed ID: 3088346
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of aztreonam therapy for serious infections due to gram-negative bacteria.
McKellar PP
Rev Infect Dis; 1985; 7 Suppl 4():S803-9. PubMed ID: 3909340
[TBL] [Abstract][Full Text] [Related]
9. Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria.
Cox CE
Rev Infect Dis; 1985; 7 Suppl 4():S767-71. PubMed ID: 3909335
[TBL] [Abstract][Full Text] [Related]
10. [Antibacterial activities of monobactams against fresh clinical isolates].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukayama S; Nishimura Y; Oda S; Tanaka S; Kato M; Sato K
Jpn J Antibiot; 1988 Nov; 41(11):1600-22. PubMed ID: 3210297
[TBL] [Abstract][Full Text] [Related]
11. Aztreonam in the therapy of nosocomial infections in patients with impaired host defenses.
Cristiano P; Iovene MR; Paradisi F
Chemioterapia; 1985 Apr; 4(2):182-5. PubMed ID: 3891117
[TBL] [Abstract][Full Text] [Related]
12. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia.
Schentag JJ; Vari AJ; Winslade NE; Swanson DJ; Smith IL; Simons GW; Vigano A
Am J Med; 1985 Feb; 78(2A):34-41. PubMed ID: 3881947
[TBL] [Abstract][Full Text] [Related]
13. Treatment of serious gram-negative infections with aztreonam.
Greenberg RN; Reilly PM; Luppen KL; McMillian R; Bollinger M; Wolk SM; Darji TB; Noorani AA
J Infect Dis; 1984 Nov; 150(5):623-30. PubMed ID: 6541672
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of aztreonam: a synthetic monobactam. A comparative study with thirteen other antibiotics.
Paradelis AG; Stathopoulos GA; Salpigides GN; Crassaris LG
Methods Find Exp Clin Pharmacol; 1983; 5(6):375-83. PubMed ID: 6684718
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis.
Hessen MT; Ingerman MJ; Kaufman DH; Weiner P; Santoro J; Korzeniowski OM; Boscia J; Topiel M; Bush LM; Kaye D
Am J Med; 1987 Apr; 82(4A):262-5. PubMed ID: 3555045
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of aztreonam in the treatment of patients with renal failure.
Sion ML; Pyrpasopoulos M; Nicolaidis P; Papagianni C; Tsurutsoglu G
Rev Infect Dis; 1991; 13 Suppl 7():S652-4. PubMed ID: 2068477
[TBL] [Abstract][Full Text] [Related]
17. [Antibacterial activity of aztreonam against clinical isolates].
Igari J
Jpn J Antibiot; 1994 May; 47(5):502-20. PubMed ID: 8051793
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
LeFrock JL; Smith BR; Chandrasekar P; Rolston KV; Molavi A; Kannangara W
Arch Intern Med; 1987 Feb; 147(2):325-8. PubMed ID: 3813751
[TBL] [Abstract][Full Text] [Related]
19. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
[TBL] [Abstract][Full Text] [Related]
20. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Brogden RN; Heel RC
Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
